Pei-Fen Kuan

Professor

Stony Brook University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

We conducted a systematic assessment of computational models—CellDMC, TCA, HIRE, TOAST, and CeDAR—for detecting cell-type-specific differential methylation CpGs in bulk methylation data profiled using the Illumina DNA Methylation BeadArrays. This assessment was performed through simulations and case studies involving two epigenome-wide association studies (EWAS) on rheumatoid arthritis and major depressive disorder. Our evaluation provided insights into the strengths and limitations of each model. The results revealed that the models varied in performance across different metrics, sample sizes, and computational efficiency. Additionally, we proposed integrating the results from these models using the minimum p-value ($minpv$) and average p-value ($avepv$) approaches. Our findings demonstrated that these aggregation methods significantly improved performance in identifying cell-type-specific differential methylation CpGs.

Year:

2025

Clonal hematopoiesis of indeterminate potential (CHIP) represents the presence of clonal somatic mutations in blood cells in otherwise healthy individuals. While CHIP is known to increase risk for hematologic malignancies and cardiovascular disease, its association with airborne carcinogens remains largely unknown. We investigated CHIP mutations in 9/11 World Trade Center (WTC) disaster responders (n=350), who experienced substantial exposure to a complex mix of airborne carcinogens. Ultra-deep whole-exome sequencing at 250X was performed on banked blood samples. We characterized CHIP mutations and their associations with clinical factors (age, ancestry, gender, body mass index, cardiovascular disease, stroke), laboratory parameters (peripheral blood counts), mental and cognitive assessments, exposure data, and HLA zygosity. Statistical methods included Fisher’s exact test, Wilcoxon rank sum test, and multivariate logistic regression. Findings were compared to unexposed controls (n=293) analyzed using identical methods. Among WTC participants, CHIP prevalence was 34.2%, with myeloid-CHIP (M-CHIP) at 16.2% and lymphoid-CHIP (L-CHIP) at 21.4%. M-CHIP prevalence correlated positively with age ( p =0.02), smoking history ( p= 0.01), and lower platelet counts ( p =0.03). The most frequent M-CHIP mutations were in DNMT3A, TET2, PPM1D , while L-CHIP mutations were in EEF1A1, DDX11 and KMT2D . Notably, DDX11 mutations were associated with lower Montreal Cognitive Assessment scores ( p =6.57e-03). Comparison with unexposed controls demonstrated higher CHIP prevalence in WTC responders, particularly in those 55 or younger. Study highlights the potential utility of deep sequencing for CHIP detection with clinical, laboratory and exposure data to develop personalized risk-adapted screening programs for cancer and other CHIP-related conditions in individuals exposed to airborne carcinogens.

Year:

2024

The search for prognostic biomarkers capable of predicting patient outcomes, by analyzing gene expression in tissue samples and other molecular profiles, remains largely on single-gene-based or global-gene-search approaches. Gene-centric approaches, while foundational, fail to capture the higher-order dependencies that reflect the activities of co-regulated processes, pathway alterations, and regulatory networks, all of which are crucial in determining the patient outcomes in complex diseases like cancer. Here, we introduce GPS-Net, a computational framework that fills the gap in efficiently identifying prognostic modules by incorporating the holistic pathway structures and the network of gene interactions. By innovatively incorporating advanced multiple kernel learning techniques and network-based regularization, the proposed method not only enhances the accuracy of biomarker and pathway identification but also significantly reduces computational complexity, as demonstrated by extensive simulation studies. Applying GPS-Net, we identified key pathways that are predictive of patient outcomes in a cancer immunotherapy study. Overall, our approach provides a novel framework that renders genome-wide pathway-level prognostic analysis both feasible and scalable, synergizing both mechanism-driven and data-driven for precision genomics.

Year:

2024

We performed systematic assessment of computational deconvolution methods that play an important role in the estimation of cell type proportions from bulk methylation data. The proposed framework methylDeConv (available as an R package) integrates several deconvolution methods for methylation profiles (Illumina HumanMethylation450 and MethylationEPIC arrays) and offers different cell-type-specific CpG selection to construct the extended reference library which incorporates the main immune cell subsets, epithelial cells and cell-free DNAs. We compared the performance of different deconvolution algorithms via simulations and benchmark datasets and further investigated the associations of the estimated cell type proportions to cancer therapy in breast cancer and subtypes in melanoma methylation case studies. Our results indicated that the deconvolution based on the extended reference library is critical to obtain accurate estimates of cell proportions in non-blood tissues.

Year:

2022

Collaborators (28)

Robert Klein

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Benjamin Luft

Edmund D. Pellegrino Professor

Stony Brook University

UNITED STATES
View details

Yuting Lu

New York University

UNITED STATES
View details

Graham Mann

Professor

University of Sydney

AUSTRALIA
View details

Adam Reynolds

Research Assistant Professor

University of New Mexico

UNITED STATES
View details

Shaofeng Yan

-

UNITED STATES
View details

Paolo Boffetta

Stony Brook University

UNITED STATES
View details

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Cheryl Thompson

Professor and Associate Director for Population Sciences, Penn State Cancer Institute

Pennsylvania State University

UNITED STATES
View details

Zeynep Gümüş

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Christopher I. Amos

Associate Director for Population and Data Science

Baylor College of Medicine

UNITED STATES
View details

Pauline Funchain

Stanford University

UNITED STATES
View details

Marcus Bosenberg

Professor

Yale University

UNITED STATES
View details

Myvizhi Esai Selvan

Senior Scientist

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Marianne Berwick

Professor

University of New Mexico

UNITED STATES
View details

David Ollila

Professor of Surgery

University of North Carolina at Chapel Hill

UNITED STATES
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

Anne E Cust

Deputy Director, The Daffodil Centre

University of Sydney

AUSTRALIA
View details

David Polsky

Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)

NYU School of Medicine

UNITED STATES
View details

Tim Lee

The University of British Columbia

UNITED STATES
View details

Paul Googe

Professor and Laboratory Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Iman Osman

NYU Langone Health

UNITED STATES
View details

Eva Hernando

Professor

NYU Langone Medical Center

UNITED STATES
View details

Sheri L. Holmen

Professor

University of Utah Health Sciences Center

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

E. Nagore

Profesor Asociado

Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología

SPAIN
View details